Prostate Cancer: Molecular Imaging and Magnetic Resonance Imaging (MRI)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 15 June 2024 | Viewed by 1480
Special Issue Editor
2. Onze Lieve Vrouw Hospital, Aalst, Belgium
Interests: urologic oncology; diagnosis; treatment; surgical training; robotic surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer is the second most commonly diagnosed cancer in men worldwide. Accurate diagnosis and staging are crucial for determining the appropriate treatment approach and predicting patient outcomes. Over the past few years, magnetic resonance imaging (MRI) and molecular imaging have revolutionized the diagnostic‒therapeutic pathway of prostate cancer. MRI has transformed prostate gland imaging, offering high-resolution anatomical details and functional information. Multiparametric MRI, combining T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging, enhances the detection, localization, and characterization of prostate tumors. Molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), enable the visualization and characterization of specific molecular targets and metabolic processes associated with prostate cancer. These cutting-edge techniques offer invaluable insights into tumor aggressiveness, lymph node involvement, and distant metastases. Additionally, emerging techniques such as magnetic resonance spectroscopy and radiomics analysis offer further understanding of tumor biology and behavior. The integration of molecular imaging and MRI holds great potential in improving the accuracy of prostate cancer diagnosis, risk stratification, and treatment planning, ultimately leading to more personalized approaches and improved patient outcomes.
Nevertheless, there are several open issues that researchers and clinicians must address. Standardized protocols and criteria are needed to ensure consistent and reliable results across different centers and studies. Cost-effectiveness and accessibility concerns need to be addressed to make these advanced imaging modalities widely available. Integration with other diagnostic modalities, such as prostate biopsy or biomarkers, is of utmost importance to enhance overall diagnostic accuracy. Furthermore, long-term outcome studies are crucial to evaluate the prognostic value of molecular imaging and MRI in prostate cancer. Understanding the correlation between these imaging modalities, treatment response, disease progression, and overall survival is pivotal in establishing their role in clinical practice.
This Special Issue aims to shed light on the current state of molecular imaging and MRI for prostate cancer, with a particular focus on addressing the aforementioned challenges. By showcasing the latest research and advancements in this field, we strive to advance the field of molecular imaging and MRI for prostate cancer and pave the way for more precise and personalized approaches in its management.
Dr. Marco Paciotti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- prostate imaging
- diagnosis
- clinical staging
- magnetic resonance imaging (MRI)
- fusion biopsy
- molecular imaging
- positron emission tomography (PET)
- PSMA PET/CT
- PSMA-based therapy
